vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Vanda Pharmaceuticals Inc. is the larger business by last-quarter revenue ($57.2M vs $34.3M, roughly 1.7× Clearfield, Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -246.8%, a 245.0% gap on every dollar of revenue. On growth, Vanda Pharmaceuticals Inc. posted the faster year-over-year revenue change (7.6% vs -3.2%). Clearfield, Inc. produced more free cash flow last quarter ($-2.4M vs $-29.5M). Over the past eight quarters, Vanda Pharmaceuticals Inc.'s revenue compounded faster (9.8% CAGR vs -3.5%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
CLFD vs VNDA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $57.2M |
| Net Profit | $-614.0K | $-141.2M |
| Gross Margin | 33.2% | — |
| Operating Margin | -5.3% | -70.5% |
| Net Margin | -1.8% | -246.8% |
| Revenue YoY | -3.2% | 7.6% |
| Net Profit YoY | 67.8% | -2774.3% |
| EPS (diluted) | $-0.04 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $57.2M | ||
| Q3 25 | $23.4M | $56.3M | ||
| Q2 25 | $49.9M | $52.6M | ||
| Q1 25 | $47.2M | $50.0M | ||
| Q4 24 | $29.7M | $53.2M | ||
| Q3 24 | $5.6M | $47.7M | ||
| Q2 24 | $48.8M | $50.5M | ||
| Q1 24 | $36.9M | $47.5M |
| Q4 25 | $-614.0K | $-141.2M | ||
| Q3 25 | $-9.1M | $-22.6M | ||
| Q2 25 | $1.6M | $-27.2M | ||
| Q1 25 | $1.3M | $-29.5M | ||
| Q4 24 | $-1.9M | $-4.9M | ||
| Q3 24 | — | $-5.3M | ||
| Q2 24 | $-447.0K | $-4.5M | ||
| Q1 24 | $-5.9M | $-4.1M |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | -70.5% | ||
| Q3 25 | 10.3% | -55.6% | ||
| Q2 25 | 3.0% | -73.2% | ||
| Q1 25 | 0.6% | -82.0% | ||
| Q4 24 | -6.9% | -19.3% | ||
| Q3 24 | — | -23.1% | ||
| Q2 24 | -4.7% | -20.1% | ||
| Q1 24 | -26.4% | -19.5% |
| Q4 25 | -1.8% | -246.8% | ||
| Q3 25 | -38.8% | -40.1% | ||
| Q2 25 | 3.2% | -51.7% | ||
| Q1 25 | 2.8% | -58.9% | ||
| Q4 24 | -6.4% | -9.2% | ||
| Q3 24 | — | -11.2% | ||
| Q2 24 | -0.9% | -9.0% | ||
| Q1 24 | -16.0% | -8.7% |
| Q4 25 | $-0.04 | $-2.40 | ||
| Q3 25 | $-0.65 | $-0.38 | ||
| Q2 25 | $0.11 | $-0.46 | ||
| Q1 25 | $0.09 | $-0.50 | ||
| Q4 24 | $-0.13 | $-0.09 | ||
| Q3 24 | — | $-0.09 | ||
| Q2 24 | $-0.04 | $-0.08 | ||
| Q1 24 | $-0.40 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $249.7M | $327.2M |
| Total Assets | $268.1M | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $84.9M | ||
| Q3 25 | $106.0M | $70.0M | ||
| Q2 25 | $117.2M | $81.0M | ||
| Q1 25 | $112.0M | $111.8M | ||
| Q4 24 | $113.0M | $102.3M | ||
| Q3 24 | $129.0M | $100.5M | ||
| Q2 24 | $123.8M | $103.0M | ||
| Q1 24 | $142.9M | $125.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $249.7M | $327.2M | ||
| Q3 25 | $256.2M | $466.0M | ||
| Q2 25 | $264.5M | $486.3M | ||
| Q1 25 | $265.9M | $511.4M | ||
| Q4 24 | $267.4M | $538.5M | ||
| Q3 24 | $275.8M | $541.2M | ||
| Q2 24 | $274.6M | $542.5M | ||
| Q1 24 | $279.2M | $544.0M |
| Q4 25 | $268.1M | $488.9M | ||
| Q3 25 | $306.2M | $601.1M | ||
| Q2 25 | $314.7M | $624.7M | ||
| Q1 25 | $310.9M | $631.9M | ||
| Q4 24 | $303.2M | $656.2M | ||
| Q3 24 | $315.3M | $645.1M | ||
| Q2 24 | $318.1M | $651.4M | ||
| Q1 24 | $315.4M | $652.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $-29.4M |
| Free Cash FlowOCF − Capex | $-2.4M | $-29.5M |
| FCF MarginFCF / Revenue | -7.1% | -51.6% |
| Capex IntensityCapex / Revenue | 2.9% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $-29.4M | ||
| Q3 25 | — | $-31.6M | ||
| Q2 25 | $7.9M | $-15.3M | ||
| Q1 25 | $3.0M | $-33.1M | ||
| Q4 24 | $7.2M | $-1.8M | ||
| Q3 24 | $22.2M | $-14.6M | ||
| Q2 24 | $4.0M | $-6.9M | ||
| Q1 24 | $-5.7M | $7.6M |
| Q4 25 | $-2.4M | $-29.5M | ||
| Q3 25 | — | $-31.8M | ||
| Q2 25 | $7.5M | $-15.6M | ||
| Q1 25 | $654.0K | $-33.6M | ||
| Q4 24 | $5.1M | $-2.0M | ||
| Q3 24 | $18.2M | $-14.7M | ||
| Q2 24 | $2.8M | $-7.0M | ||
| Q1 24 | $-7.7M | $7.6M |
| Q4 25 | -7.1% | -51.6% | ||
| Q3 25 | — | -56.5% | ||
| Q2 25 | 15.1% | -29.6% | ||
| Q1 25 | 1.4% | -67.1% | ||
| Q4 24 | 17.1% | -3.8% | ||
| Q3 24 | 323.0% | -30.9% | ||
| Q2 24 | 5.8% | -13.9% | ||
| Q1 24 | -20.8% | 15.9% |
| Q4 25 | 2.9% | 0.2% | ||
| Q3 25 | 2.0% | 0.3% | ||
| Q2 25 | 0.8% | 0.6% | ||
| Q1 25 | 5.1% | 0.9% | ||
| Q4 24 | 7.0% | 0.4% | ||
| Q3 24 | 71.4% | 0.3% | ||
| Q2 24 | 2.5% | 0.2% | ||
| Q1 24 | 5.3% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLFD
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
